Nasopharyngeal carcinoma, susceptibility to, 1
MONDO:0011775Any nasopharyngeal carcinoma in which the cause of the disease is a mutation in the TP53 gene.
Also known as: TP53 nasopharyngeal carcinoma, nasopharyngeal carcinoma 1, nasopharyngeal carcinoma caused by mutation in TP53, nasopharyngeal carcinoma, somatic, nasopharyngeal carcinoma, susceptibility to, 1, NPC, Npca, nasopharyngeal cancer
53 clinical trials for this condition and its sub-types, 21 tagged with Nasopharyngeal carcinoma, susceptibility to, 1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Sharper radiation boost aims to tackle head and neck cancers that return
Disease control OngoingThis phase 1 study tests whether adding a highly targeted, high-dose radiation boost (stereotactic body radiotherapy, or SBRT) to standard radiation and chemotherapy can safely treat head and neck cancer that has come back or spread. The trial includes two groups: patients whose …
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug targets virus to fight rare cancer
Disease control OngoingThis phase 2 trial tests a drug called VK-2019 in 13 patients with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has returned or spread and has no standard treatment. VK-2019 works by blocking a key viral protein, EBNA1, which the virus needs to survive. The main g…
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Immune cells trained to fight advanced throat cancer in new trial
Disease control OngoingThis early-phase study tests whether a personalized immune cell therapy (dendritic cells) is safe and can help control advanced nasopharyngeal cancer. The treatment uses the patient's own immune cells and donor cell secretions to boost the body's cancer fight. The study involves …
Phase 1/2 • Sponsor: PT. Prodia Stem Cell Indonesia • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Donor immune cells take on Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …
Phase 1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy shows promise for advanced nose cancer
Disease control OngoingThis study tests a treatment plan for people with stage IVA nasopharyngeal cancer (a type of nose and throat cancer). Participants receive a combination of the immunotherapy drug pembrolizumab and chemotherapy before and during radiation, followed by maintenance pembrolizumab for…
Phase 2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Mouth rinse could ease painful radiation side effects for head and neck cancer patients
Symptom relief OngoingThis trial tests Gelclair, a mouth rinse that forms a protective coating over the mouth's lining, to see if it eases the painful mouth sores (oral mucositis) caused by radiation therapy for head and neck cancer. The study enrolls adults with squamous cell carcinoma who will recei…
Phase 4 • Sponsor: McMaster University • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC